Category: Biotech
-
Numinus Wellness (NUMI.V) to partner on MDMA psychotherapy trial for PTSD patients
If this was a 1990’s news website we’d be putting all sorts of animated siren gifs all over the top of this piece because, I ain’t gonna lie: It’s a big one. Numinus Wellness (NUMI.V), who we’ve been eyeing at a distance for some time because we love shrooms as an industry but don’t trust…
-
![Revive (RVV.C) stock ramps hard on news from a collaborator]()
Revive (RVV.C) stock ramps hard on news from a collaborator
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”.
-
Sixth Wave (SIXW.C) partners with super-star research institution – potential pipeline accelerator
Dr. Houghton – a Director and Research Chair holder at Li Ka Shing – just won a Nobel Prize.
-
![Revive (RVV.C) advances mushroom bio-tech as new regs change the game]()
Revive (RVV.C) advances mushroom bio-tech as new regs change the game
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison”. RVV is a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders.…
-
![Sixth Wave (SIXW.C) gets $250,000 Covid-19 development money from Nova Scotia]()
Sixth Wave (SIXW.C) gets $250,000 Covid-19 development money from Nova Scotia
SIXW is a nanotechnology company focusing on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs).
-
Revive Therapeutics (RVV.C) to have 10 clinical COVID-19 FDA trial sites by end of year
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the thought that a three time loser might be relevant in 2020. Having missed on an earlier pharma focus, and come to the cannabis party a little…
-
Perimeter Medical Imaging AI (PINK.V) isn’t messing about: Let’s make breast cancer treatment better – and profitable!
In the North American biotech space, you hear a lot of ‘promise’ from companies and their teams. Lots of ‘we’re going to take this to trial’, and a lot of ‘billion dollar industry’ talk. Lots of early stage bets, a little over-hype perhaps. For the most part, you’re being asked to invest in technologies that…
-
Perimeter Medical Imaging AI (PINK.V) shuffles the deck
PINK is accelerating toward the commercialisation of the OTIS platform. It has already received a $7.4 million grant (non-dilutive capital) from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the ATLAS AI Project.
-
NeuPath Health Inc (NPTH.V): Where a little attention could go a long way
“In Canada, it’s not fundamentals, but sentiment that moves markets”…boy, if I had a nickel for everytime I heard that, I would have invested in Well Health Technologies (WELL.T) (nothing against $WELL!), and I would have been a couple of thousand dollars richer. If only there was a way to prove that. Allow me: It…
-
Aequus Pharmaceuticals (AQS.V) gets Health Canada device licence approval, validates business model
Aequus Pharmaceuticals (AQS.V), a specialty pharma company with a business model of acquiring and re-platforming existing approved biotech and health products to appeal to a wider market, has announced another win Monday morning with news Health Canada has approved the advancing of their Evolve dry-eye relief gel line to an easy-squeeze eye drop bottle. Admittedly,…
